Indian Council of Medical Research criticizes a recently-published study on Covaxin’s safety analysis for poor methodology. The study wrongly acknowledges ICMR. Director Rajiv Bahl clarifies the lack of comparison group for side effects attribution. Nearly one-third of Covaxin recipients reported adverse events. ICMR warns of legal action for unapproved acknowledgements.
